SLC5A2 and chronic kidney disease: In particular, the effectiveness of SGLT2 inhibitors in lowering glucose levels decreases as kidney function decreases, resulting in reduced efficacy in patients with advanced CKD (estimated glomerular filtration rate (eGFR) <30 mL/min) 9.